MARKET

WINT

WINT

Windtree Therapeutics Inc
NASDAQ
0.8280
-0.0020
-0.24%
After Hours: 0.8100 -0.018 -2.17% 19:04 05/16 EDT
OPEN
0.8300
PREV CLOSE
0.8300
HIGH
0.8699
LOW
0.8030
VOLUME
164.93K
TURNOVER
--
52 WEEK HIGH
737.44
52 WEEK LOW
0.8030
MARKET CAP
3.02M
P/E (TTM)
-0.0079
1D
5D
1M
3M
1Y
5Y
1D
Windtree Therapeutics Inc. Reports Q1 2025 Financial Results
TipRanks · 20h ago
Windtree Therapeutics announces resale of 42.17M shares by selling stockholders
Seeking Alpha · 1d ago
Windtree Therapeutics files to sell 42.17M shares of common stock for holders
TipRanks · 1d ago
Windtree Therapeutics GAAP EPS of -$4.63
Seeking Alpha · 1d ago
Windtree Therapeutics Q4 EPS $(4.63) Beats $(28.82) Estimate
Benzinga · 1d ago
Windtree Therapeutics reports Q1 EPS ($4.63)
TipRanks · 1d ago
*Windtree Therapeutics Cash and Cash Equivalents of $1.2M and Current Liabilities of $6.5M at March 31 >WINT
Dow Jones · 1d ago
*Windtree Therapeutics 1Q Loss/Shr $4.63 >WINT
Dow Jones · 1d ago
More
About WINT
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.

Webull offers Windtree Therapeutics Inc stock information, including NASDAQ: WINT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WINT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading WINT stock methods without spending real money on the virtual paper trading platform.